- Home
- WF vs SRPT Comparison
WF vs SRPT Comparison
Compare WF & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WF
- SRPT
- Stock Information
- Founded
- WF 1899
- SRPT 1980
- Country
- WF South Korea
- SRPT United States
- Employees
- WF N/A
- SRPT N/A
- Industry
- WF Commercial Banks
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- WF Finance
- SRPT Health Care
- Exchange
- WF Nasdaq
- SRPT Nasdaq
- Market Cap
- WF 8.2B
- SRPT 9.8B
- IPO Year
- WF N/A
- SRPT 1997
- Fundamental
- Price
- WF $35.75
- SRPT $60.44
- Analyst Decision
- WF
- SRPT Buy
- Analyst Count
- WF 0
- SRPT 22
- Target Price
- WF N/A
- SRPT $153.50
- AVG Volume (30 Days)
- WF 80.7K
- SRPT 2.8M
- Earning Date
- WF 05-15-2025
- SRPT 05-06-2025
- Dividend Yield
- WF 5.16%
- SRPT N/A
- EPS Growth
- WF 22.27
- SRPT N/A
- EPS
- WF 2.67
- SRPT 2.34
- Revenue
- WF $7,762,228,247.00
- SRPT $1,901,979,000.00
- Revenue This Year
- WF N/A
- SRPT $66.51
- Revenue Next Year
- WF $9.38
- SRPT $21.66
- P/E Ratio
- WF $4.49
- SRPT $25.85
- Revenue Growth
- WF 20.71
- SRPT 52.97
- 52 Week Low
- WF $29.44
- SRPT $48.01
- 52 Week High
- WF $38.05
- SRPT $173.25
- Technical
- Relative Strength Index (RSI)
- WF 59.16
- SRPT 43.26
- Support Level
- WF $29.44
- SRPT $58.76
- Resistance Level
- WF $37.39
- SRPT $62.78
- Average True Range (ATR)
- WF 1.51
- SRPT 3.87
- MACD
- WF 0.36
- SRPT 2.51
- Stochastic Oscillator
- WF 79.41
- SRPT 84.16
About WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holdings company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. Its operating segments include Banking, Credit card, capital, Investment banking, and others.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.